HomeAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
Nakaraang pagsara
$5.66
Sakop ng araw
$5.35 - $5.80
Sakop ng taon
$1.58 - $19.95
Market cap
347.84M USD
Average na Volume
1.82M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 416.00K | -99.59% |
Gastos sa pagpapatakbo | 17.83M | -63.41% |
Net na kita | -72.70M | -447.98% |
Net profit margin | -17.48K | -85,981.67% |
Kita sa bawat share | -1.07 | -456.67% |
EBITDA | -75.44M | -496.59% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 234.40M | -33.98% |
Kabuuang asset | 250.71M | -46.27% |
Kabuuang sagutin | 54.51M | 13.13% |
Kabuuang equity | 196.20M | — |
Natitirang share | 68.55M | — |
Presyo para makapag-book | 1.98 | — |
Return on assets | -64.90% | — |
Return on capital | -81.67% | — |
Cash Flow
Net change in cash
| (USD) | Set 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -72.70M | -447.98% |
Cash mula sa mga operasyon | -41.57M | -704.22% |
Cash mula sa pag-invest | 38.82M | 135.91% |
Cash mula sa financing | 80.00K | -91.00% |
Net change in cash | -2.44M | 97.83% |
Malayang cash flow | -86.18M | -1,426.30% |
Tungkol
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Itinatag
2013
Website
Mga Empleyado
384
